A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 27 Jul 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2016.
- 27 Jul 2016 Planned primary completion date changed from 1 May 2017 to 1 Dec 2016.